| Literature DB >> 31175522 |
Rodrigo Sudatti Delevatti1,2, Cláudia Gomes Bracht3, Salime Donida Chedid Lisboa3, Rochelle Rocha Costa3, Elisa Corrêa Marson3, Nathalie Netto3, Luiz Fernando Martins Kruel3.
Abstract
BACKGROUND: Aerobic training (AT) improves glycemic control in patients with type 2 diabetes. However, the role of the progression of training variables remains unclear. The objective of this review was to analyze the effects of progressive AT (PAT) and non-progressive AT (NPAT) on glycated hemoglobin (HbA1c) in patients with type 2 diabetes.Entities:
Keywords: Diabetes mellitus; Exercise; Glycated hemoglobin
Year: 2019 PMID: 31175522 PMCID: PMC6555839 DOI: 10.1186/s40798-019-0194-z
Source DB: PubMed Journal: Sports Med Open ISSN: 2198-9761
Fig. 1Flow of information through the different phases of the systematic review
Characteristics of the included studies
| Study | Age (years) | HbA1c baseline (%) | Training status | Comorbidities | Nutritional co-intervention | Adverse events | Adherence (%) | Drop-outs |
|---|---|---|---|---|---|---|---|---|
| Progressive aerobic training | ||||||||
| Alvarez et al. 2016 [ | 45 ± 2 | I: 7.0 ± 0.5 C: 7.4 ± 0.5 | Untrained | Overweight and obesity | No | Post-exercise hypoglycemia | 89 | I: 0% C: 29% |
| Belli et al. 2011 [ | 54 ± 2 | I: 6.8 ± 0.4 C: 7.2 ± 0.5 | Untrained | NR | No | NR | 92 | I: 33% C: 20% |
| Kadoglou et al. 2007 [ | 61 ± 4 | I: − 0.6 ± 0.4* C: 0.3 ± 0.1* | Untrained | NR | No | No | NR | I: 3% C: 11% |
| Kadoglou et al. 2012 [ | 58 ± 6 | I: − 0.6 ± 0.1* C: − 0.05 ± 0.01* | Untrained | Overweight and obesity | Standard nutritional prescription, orientation | No | NR | I: 10% C: 14% |
| Lambers et al. 2008 [ | 54 ± 8 | I: 7.4 ± 1.7 C: 6.7 ± 0.9 | NR | Obesity, cardiovascular risk | No | Hypoglycemia | 85% | I: 28% C: 17% |
| Mitranun et al. 2014 [ | 61 ± 2 | I (Interval): 7.6 ± 0.3 I (Continuous): 7.7 ± 2.0 C: 7.8 ± 2.0 | Untrained | NR | No | NR | At least 80% | I: 7% C: 13% |
| Negri et al. 2010 [ | 65 ± 5 | I: 7.5 ± 0.2 C: 7.4 ± 0.5 | Untrained | NR | No | Hypoglycemia | At least 50% | I: 33% C: 5% |
| Oliveira et al. 2012 [ | 52 ± 9 | I: 7.4 ± 1.8 C: 7.0 ± 0.7 | Untrained | NR | No | Hypoglycemia, hypotension | NR | I: 11% C: 31% |
| Sentinelli et al. 2014 [ | 57 ± 7 | I: 7.1 ± 1.3 C: 7.1 ± 1.3 | Untrained | NR | No | NR | NR | I: 0% C: 0% |
| Tomar et al. 2013 [ | 43 ± 10 | I: 8.3 ± 3.5 C: 8.9 ± 5.9 | Untrained | NR | No | No | 100% | I: 17% C: 0% |
| Vancea et al. 2009 [ | 57 ± 6 | I: − 0.8 ± 1.4* C: − 0.3 ± 0.4* | NR | NR | No | NR | NR | NR |
| Yavari et al. 2012 [ | 49 ± 8 | I: 8.5 ± 1.1 C: 8.7 ± 1.1 | Untrained | NR | No | NR | 80% | I: 19% C: 19% |
| Non-progressive aerobic training | ||||||||
| Blonk et al. 1994 [ | 58.7* | I: − 1.0 ± 4.7* C: − 0.1 ± 9.5* | NR | NR | Yes | NR | NR | I: 12% C: 15% |
| Church et al. 2010 [ | 56 ± 8 | I: 7.5 ± 0.6 C: 7.61 ± 0.64 | Untrained | NR | No | No | NR | NR |
| Emereziani et al. 2015 [ | 66 ± 4 | I: 6.7 ± 1.6 C: 7.0 ± 1.5 | Untrained | NR | Yes | NR | NR | NR |
| Giannopoulou et al. 2005 [ | 57 ± 2 | I: 6.8 ± 0.5 C: 7.3 ± 0.5 | Untrained | Obesity | Yes | NR | NR | I: 21% C: 39% |
| Jorge et al. 2011 [ | 53 ± 9 | I: 7.6 ± 1.7 C: 6.9 ± 0.7 | Untrained | Overweight and obesity | No | NR | 97% | I: 10% C:31% |
| Karstoft et al. 2013 [ | 58 ± 2 | I (Continuous): 6.6 ± 0.2 I (Interval): 6.9 ± 0.2 Control: 6.4 ± 0.2 | Untrained | NR | No | NR | 89% | I: 9% C: 0% |
| Kwon et al. 2011 [ | 65 ± 6 | I: 7.5 ± 0.7 C: 7.2 ± 0.8 | Untrained | Overweight | No | NR | NR | I: 9% C: 0% |
| Midlebrooke et al. 2006 [ | 63 ± 7 | I: 6.8 ± 0.9 C: 7.2 ± 1.1 | Physically active and untrained | Proliferative retinopathy, sensory neuropathy, autonomic neuropathy, microalbuminuria | No | No | 80% | I: 47% C: 0% |
| Nuttamonwarakul et al. 2012 [ | > 60 | I: 7.7 ± 1.1 C: 7.6 ± 0.2 | NR | NR | No | NR | NR | NR |
| Parra-Sanchez et al. 2015 [ | 72 ± 4 | I: 7.0 ± 0.9 C: 7.3 ± 1.1 | Untrained | NR | No | No | NR | I: 6% C: 22% |
| Shenoy et al. 2009 [ | 55 ± 5 | I: 8.1 ± 0.9 C: 7.8 ± 0.9 | Untrained | NR | No | No | NR | NR |
| Yan et al. 2014 [ | 54 ± 2 | I: 8.8 ± 0.5 C: 8.4 ± 0.9 | Physically active | NR | No | NR | NR | NR |
I intervention, C control, HbA1c glycated hemoglobin. * indicates values of HbA1c demonstrated in changes (post-pre intervention and control) and not by baseline values
Characteristics of the interventions
| Study | Modality ( | Intervention period | Session duration | Weekly frequency | Weekly duration | Intensity | Volume |
|---|---|---|---|---|---|---|---|
| Progressive aerobic training | |||||||
| Alvarez et al. 2016 [ | Interval: stimulus—running, recovery—walking ( Control ( | 16 weeks | Beginning: 22 min Final: 37.5 min | 3 | Beginning: 66 min Final: 112.6 min | Stimulus: 90–100% HRres Recovery: ≤ 70% HRres | – |
| Belli et al. 2011 [ | Walking ( Control ( | 12 weeks | Beginning: 20 min Final: 60 min | 3 | Beginning: 60 min Final: 180 min | HRVT | – |
| Kadoglou et al. 2007 [ | Walking or running on the treadmill/cycle ergometer ( Control ( | 26 weeks | Beginning: 30 min Final: 45 min | 4 | Beginning: 120 min Final: 180 min | Beginning: 50%VO2peak Gradual increase throughout the 26 weeks Final: 75%VO2peak | – |
| Kadoglou et al. 2012 [ | Walking or running on the treadmill/cycle ergometer ( Control ( | 26 weeks | Gradual increases until 4th week, reaching 45 min | 4 | 180 min | Beginning: 60% HRmax Final: 75% HRmax | – |
| Lambers et al. 2008 [ | Walking or running/cycle ergometer ( Control ( | 12 weeks | 50 min | 3 | 150 min | Beginning: 60%HRres Middle: 75%HRre Final: 85%HRre | – |
| Mitranun et al. 2014 [ | Interval training on the treadmill (it does not report if it is walking or running in the stimulus and recovery) ( Control ( | 12 weeks | Beginning: 20 min Middle: 20 min Final: 30 min | 3 | Beginning: 60 min Middle: 60 min Final: 90 min | Beginning: 50% VO2peak Middle: 80% VO2peak Final: 85% VO2peak | Beginning: 33.6 L O2 Middle: 36.2 L O2 Final: 53.7 L O2 |
Continuous on the treadmill (does not report if it is walking or running) ( Control ( | Beginning: 20 min Middle: 20 min Final: 30 min | 3 | Beginning: 60 min Middle: 60 min Final: 90 min | Beginning: 50% VO2peak Middle: 60% VO2peak Final: 65% VO2peak | Beginning: 33.6 L O2 Middle: 36.2 L O2Final: 53.7 L O2 | ||
| Negri et al. 2010 [ | Walking ( Control ( | 16 weeks | 45 min | 3 | 135 min | Beginning: low(NS) Final: moderate (NS) | – |
| Oliveira et al. 2012 [ | Cycle ergometer ( Control ( | 12 weeks | Beginning: 20 min Final: 50 min | 3 | From 60 to 150 min | HRLT | – |
| Sentinelli et al. 2014 [ | Nordic walking ( Control ( | 12 weeks | Beginning: 60 min Final: 90 min | 3 | Beginning: 180 min Final: 270 min | Beginning: low to moderate (NS) Final: moderate to high (NS) | Beginning: 4–5 km with slope of 7% of inclination Final: 7 km with slope of 14% of inclination |
| Tomar et al. 2013 [ | Walking or running on the treadmill/cycle ergometer ( Control ( | 12 weeks | NS | 3 | Increased every 4 weeks (NS) | Beginning: 40–50% HRmax; Gradual increase (NS) | – |
| Vancea et al. 2009 [ | Walking ( Control ( | 20 weeks | 30 min | 3 | 90 min | Beginning: 60% HRmax Final: 70% HRmax | – |
Walking ( Control ( | 30 min | 5 | 150 min | Beginning: 60% HRmax Final: 70% HRmax | – | ||
| Yavari et al. 2012 [ | Treadmill/elliptical/cycle ergometer ( Control ( | 52 weeks | Beginning: 20 min Final: 60 min | 3 | Beginning: 60 min Final: 180 min | Beginning: 60% HRmax Final: 75% HRmax | – |
| Non-progressive aerobic training | |||||||
| Blonk et al. 1994 [ | Cycle ergometer ( Control ( | 26 weeks | 30 min | 2 | 60 min | 60–80%HRmax | – |
| Church et al. 2010 [ | Walking ( Control ( | 39 weeks | 50 min | 3 | 150 min | 50–80% VO2max | 12 kcal/kg/week |
| Emereziani et al. 2015 [ | Walking/cycle ergometer ( Control ( | 12 weeks | 30 min | 2 | 60 min | HRAT | – |
| Giannopolou et al. 2005 [ | Walking ( Control ( | 14 weeks | 50 min | 3 | 150 min | 65–70% VO2peak | Deficit of 200 kcal |
| Jorge et al. 2011 [ | Cycle ergometer ( Control ( | 12 weeks | 60 min | 3 | 180 min | HRLT | – |
| Karstoft et al. 2013 [ | Walking (continuous) ( Control ( | 17 weeks | 60 min | 5 | 300 min | 55% VO2peak | – |
Walking (interval) ( Control (4) | 60 min | 5 | 300 min | 70% VO2peak (3 min above, 3 min below) | – | ||
| Kwon et al. 2001 [ | Walking ( Control ( | 12 weeks | 60 min | 5 | 300 min | Moderate (NS) | 4 to 6 METs |
| Middlebrooke et al. 2006 [ | Not reported ( Control ( | 26 weeks | 30 min | 3 | 90 min | 70–80% HRmax | – |
Nuttamon- warakul et al. 2012 [ | Aquatic training ( Control ( | 12 weeks | 30 | 3 | 90 min | 70% HRmax | – |
| Parra-Sanchez et al. 2015 [ | Walking ( Control ( | 12 weeks | 40 min | 2 | 80 min | Velocity which allowed to speak without stuttering | – |
| Shenoy et al. 2009 [ | Walking ( Control ( | 16 weeks | 30 min | 3 | 90 min | – | – |
| Yan et al. 2014 [ | Not reported (low intensity) ( Control ( | 12 weeks | 45 min | 3–5 | 135 to 225 min | 50% VO2max | – |
Not reported (high intensity) ( Control ( | 45 min | 3 | 135 min | 75% VO2max | – | ||
Min minutes, n number of participants, HR heart rate reserve, HR maximum heart rate, HR heart rate corresponding to lactate threshold, HR heart rate corresponding to aerobic threshold, HR heart rate corresponding to ventilatory threshold, VO peak oxygen consumption, L O2 liters of oxygen, NS not specified. The study of Blonk et al. (1994) did not state the SD of the participants’ age
Risk of bias
| Study | Random sequence generation | Allocation concealment | Blinding of outcome assessment | Incomplete outcome data |
|---|---|---|---|---|
| Alvarez et al. 2016 [ | Low | High | Low | High |
| Belli et al. 2011 [ | Low | High | High | High |
| Kadoglou et al. 2007 [ | Low | High | High | High |
| Kadoglou et al. 2012 [ | Low | High | High | High |
| Lambers et al. 2008 [ | Low | Low | Low | High |
| Mitranun et al. 2014 [ | Low | High | High | High |
| Negri et al. 2010 [ | Low | High | High | High |
| Oliveira et al. 2012 [ | Low | High | High | High |
| Sentinelli et al. 2014 [ | Low | High | High | Low |
| Tomar et al. 2013 [ | Low | High | High | Low |
| Vancea et al. 2009 [ | Low | High | High | Low |
| Yavari et al. 2012 [ | Low | High | High | Low |
| Blonk et al. 1994 [ | High | High | Unclear | High |
| Church et al. 2010 [ | Low | High | Low | Low |
| Emereziani et al. 2015 [ | Low | High | High | Low |
| Giannopoulou et al. 2005 [ | High | High | High | High |
| Jorge et al. 2011 [ | Low | High | High | Low |
| Karstoft et al. 2013 [ | Low | High | Low | High |
| Kwon et al. 2011 [ | Low | High | High | High |
| Midlebrooke et al. 2006 [ | Low | High | High | High |
| Nuttamonwarakul et al. 2012 [ | Low | High | High | Low |
| Parra-Sanchez et al. 2015 [ | Low | Low | Low | High |
| Shenoy et al. 2009 [ | Low | High | High | High |
| Yan et al. 2014 [ | Low | High | High | Low |
Fig. 2a Standard mean differences in HbA1c observed with non-progressive aerobic training and control (no intervention). b Standard mean differences in HbA1c with progressive aerobic training and control (no intervention). (Black square) Study-specific estimates; (black diamond) pooled estimates of random-effects meta-analyses. Std diff standardized difference, CI confidence interval. Letters (a and b) subscribed indicate different aerobic training protocols in a same study
Meta-analysis results
| Analysis and sub-analysis | Number of comparisons | Meta-analysis | Heterogeneity | ||||
|---|---|---|---|---|---|---|---|
| Difference in means (%) | Effect size | 95% CI |
| ||||
| Aerobic training | 24 | − 0.65 | − 1.037 | − 1.386; − 0.688 | < 0.001 | 76% | < 0.001 |
| Non-progressive aerobic training | 13 | − 0.45 | − 0.920 | − 1.329; − 0.512 | < 0.001 | 74% | < 0.001 |
| Presence of comorbidities | 6 | − 0.33 | − 0.554 | − 1.048; − 0.061 | 0.028 | 52% | 0.065 |
| Absence of comorbidities | 3 | − 0.79 | − 1.358 | − 2.556; − 0.159 | 0.026 | 86% | < 0.001 |
| Walking/running modalities | 7 | − 0.43 | − 1.292 | − 1.856; − 0.727 | < 0.001 | 61% | 0.018 |
| Cycle ergometer modalities | 2 | – | − 0.156 | − 0.643; 0.330 | 0.529 | 0% | 0.753 |
| Untrained participants | 9 | − 0.39 | − 0.956 | − 1.382; − 0.530 | < 0.001 | 58% | 0.013 |
| Undefined participant’s training status | 2 | – | − 0.443 | − 1.646; 0.759 | 0.470 | 84% | 0.013 |
| Progressive aerobic training | 14 | − 0.84 | − 1.478 | − 2.197; − 0.759 | < 0.001 | 87% | < 0.001 |
| Presence of comorbidities | 4 | − 0.79 | − 3.061 | − 4.823; − 1.299 | 0.001 | 90% | < 0.001 |
| Absence of comorbidities | 9 | − 0.94 | − 0.699 | − 1.226; − 0.171 | 0.009 | 68% | 0.001 |
| Walking/running modalities | 7 | − 0.69 | − 1.078 | − 1.817; − 0.340 | 0.004 | 78% | < 0.001 |
| Mixed modalities | 5 | − 1.12 | − 2.614 | − 4.206; − 1.022 | 0.001 | 92% | < 0.001 |
| Untrained participants | 11 | − 0.99 | − 1.808 | − 2.688; − 0.927 | < 0.001 | 89% | < 0.001 |
| Undefined participant’s training status | 3 | – | − 0.381 | − 0.905; 0.143 | 0.154 | 0% | 0.633 |
| Progressive aerobic training (intensity) | 6 | − 0.57 | − 1.625 | − 2.903; − 0.348 | 0.013 | 92% | < 0.001 |
| Progressive aerobic training (duration) | 4 | − 0.93 | − 2.264 | − 3.603; − 0.926 | < 0.001 | 84% | < 0.001 |
| Progressive aerobic training (intensity and duration) | 6 | − 1.27 | − 1.422 | − 2.544; − 0.300 | 0.013 | 89% | < 0.001 |
Fig. 3Standard mean differences in HbA1c observed with aerobic training progressing in duration and control (no intervention). (Black square) Study-specific estimates; (black diamond) pooled estimates of random-effects meta-analyses. Std diff standardized difference, CI confidence interval
Fig. 4Standard mean differences in HbA1c observed with aerobic training progressing in intensity and control (no intervention). (Black square) Study-specific estimates; (black diamond) pooled estimates of random-effects meta-analyses. Std diff standardized difference, CI confidence interval. Letters (a and b) subscribed indicate different aerobic training protocols in a same study
Fig. 5Standard mean differences in HbA1c observed with aerobic training progressing in both intensity and duration and with control (no intervention). (Black square) Study-specific estimates; (black diamond) pooled estimates of random-effects meta-analyses. Std diff standardized difference, CI confidence interval. Letters (a and b) subscribed indicate different aerobic training protocols in a same study
Meta-regression results
| Moderator | Number of study estimates |
| 95% CI |
| |
|---|---|---|---|---|---|
| Progressive aerobic training | |||||
| Mean age | 14 | 0.045 | − 0.074; 0.166 | 0.457 | 0.00 |
| Percentage of women in the sample | 10 | − 0.007 | − 0.056; 0.041 | 0.765 | 0.00 |
| Body mass index | 13 | − 0.737 | − 1.346; − 0.128 | 0.20 | |
| Diagnosis duration | 11 | 0.076 | −0.069; 0.223 | 0.303 | 0.00 |
| Baseline HbA1c | 10 | 0.009 | −1.508; 1.318 | 0.895 | 0.00 |
| Glucose lowering drug users | 5 | − 0.080 | − 0.113; − 0.046 | < | 1.00 |
| Follow-up duration | 14 | − 0.088 | − 0.147; − 0.029 | 0.37 | |
| Weekly frequency | 14 | − 0.426 | − 1.677; 0.825 | 0.504 | 0.00 |
| Session duration | 13 | − 0.005 | − 0.055; 0.043 | 0.820 | 0.00 |
| Weekly duration | 13 | 0.001 | − 0.016; 0.017 | 0.960 | 0.00 |
| Non-progressive aerobic training | |||||
| Mean age | 12 | 0.001 | − 0.001; 0.002 | 0.442 | 0.00 |
| Percentage of women in the sample | 10 | 0.003 | − 0.013; 0.021 | 0.662 | 0.00 |
| Body mass índex | 12 | 0.096 | − 0.039; 0.232 | 0.163 | 0.00 |
| Diagnosis duration | 10 | − 0.015 | − 0.449; 0.417 | 0.942 | 0.00 |
| Baseline HbA1c | 12 | − 0.229 | − 0.898; 0.440 | 0.502 | 0.06 |
| Glucose lowering drug users | 8 | − 0.027 | − 0.099; 0.045 | 0.462 | 0.00 |
| Follow-up duration | 13 | 0.005 | − 0.046; 0.056 | 0.846 | 0.00 |
| Session duration | 13 | − 0.026 | − 0.058; 0.007 | 0.128 | 0.09 |
| Weekly frequency | 13 | − 0.536 | − 0.904; − 0.168 | 0.38 | |
| Weekly duration | 13 | − 0.005 | − 0.010; − 0.001 | 0.27 | |
Numbers in italic indicate statistical significance (p < 0.05)